Thank you!

Your email has been successfully added to our mailing list.

×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
No thanks

SGMO – sangamo therapeutics, inc. (US:NASDAQ)

DELAYED
$
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SGMO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/3
04:01 pm
sgmo
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Medium Report
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Report
3/18
11:42 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.
Low Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.
Report
3/17
04:49 pm
sgmo
Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
High Report
Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Report
3/17
04:01 pm
sgmo
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
High Report
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Report
3/6
04:05 pm
sgmo
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
High Report
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
Report
2/6
08:37 am
sgmo
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile [Yahoo! Finance]
Medium Report
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile [Yahoo! Finance]
Report
2/6
08:05 am
sgmo
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Low Report
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Report
2/1
10:00 am
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
1/30
12:00 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
1/28
01:20 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Low Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
1/27
08:02 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Report
1/26
12:00 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
1/24
12:00 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
1/23
12:28 pm
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Truist Financial Co. from $7.00 to $5.00. They now have a "buy" rating on the stock.
Medium Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Truist Financial Co. from $7.00 to $5.00. They now have a "buy" rating on the stock.
Report
1/22
11:30 am
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
1/18
12:00 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
1/16
06:45 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Low Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
1/15
10:30 am
sgmo
Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO)
Low Report
Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO)
Report
1/15
10:00 am
sgmo
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out
Low Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out
Report
1/14
10:30 am
sgmo
Did Sangamo Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SGMO
Medium Report
Did Sangamo Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SGMO
Report
1/14
10:00 am
sgmo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation
Medium Report
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation
Report
1/13
10:30 am
sgmo
Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Low Report
Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Report
1/13
10:00 am
sgmo
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Low Report
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Report
1/12
12:13 pm
sgmo
SGMO ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sangamo Therapeutics, Inc.
Medium Report
SGMO ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sangamo Therapeutics, Inc.
Report
1/12
12:00 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Report
Latest Posts

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day
Information

Information

Support

Support

Contact us

Contact us

11201 N Tatum Blvd
Suite 300-79795
Phoenix, AZ 85028
info@newsquantified.com

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

11201 N Tatum Blvd
Suite 300-79795
Phoenix, AZ 85028
info@newsquantified.com
Stay in the know news, product updates and promotions.
Copyright Ⓒ News Quanitifed LLC 2012-2025, All product trademarks, names, logos, and brands are property of their respective owners. Image(s) or Footage (as applicable), used under license from Shutterstock.com. 3.0.0